<!DOCTYPE html>
<html>

<head>
    <title>RWD Wall</title>
    <link rel="stylesheet" type="text/css" media="screen" href="css/styles.css" />
    <script src="js/jquery.min.js"></script>
    <script src="js/jquery.slides.js"></script>
    <!--<script src="js/attrchange.js"></script>-->
    <script src="/socket.io/socket.io.js"></script>
    <script src="js/receiver.js"></script>
    
    <!-- Google Analytics -->
    <script>
        window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;
        ga('create', 'UA-75280847-1', 'auto'); //set to none as it's set on localhost

ga(function(tracker) {
    //var clientId = tracker.get('clientId');
    //console.log(clientId);
    //console.log(tracker);
});


        ga('send', 'pageview');
    </script>
    <script async src='https://www.google-analytics.com/analytics.js'></script>
    <!-- End Google Analytics -->
    
</head>

<body>
   
    <section id="Container" class=""> <!--insert Phase_2 class here-->
        <!--Slideshow container-->
        <div id="slides_container">
            <div class="slides">
                <img src="images/Profile_1.jpg" alt="" class="Profile_1 current">
                <img src="images/Profile_2.jpg" alt="" class="Profile_2">
                <img src="images/Profile_3.jpg" alt="" class="Profile_3">
                <img src="images/Profile_4.jpg" alt="" class="Profile_4"> 
            </div>
        </div>
       
        <!--video section: both 'screensaver' and transition profile videos load here-->
        <div id="video_container" class="">
            <video class="Profile" id="Profile_1">
                <source src="video/Profile_1.mp4" type="video/mp4">
            </video>
            <video class="Profile" id="Profile_2">
                <source src="video/Profile_2.mp4" type="video/mp4">
            </video>
            <video class="Profile" id="Profile_3">
                <source src="video/Profile_3.mp4" type="video/mp4">
            </video>
            <video class="Profile" id="Profile_4">
                <source src="video/Profile_4.mp4" type="video/mp4">
            </video>
        </div>

        <!--header is used for heading titles-->
        <header>
            <h2 class="preheader">From clinical trials to clinical practice:</h2>
            <h1>real world data for HARVONI<span class="triangle"></span></h1>
        </header>

        <section id="Bio"></section>
        
        <!--Patient Navigation-->
        <nav id="Patients">
            <ul>
                <li class="Profile_1"></li>
                <li class="Profile_2"></li>
                <li class="Profile_3"></li>
                <li class="Profile_4"></li>
            </ul>
        </nav>
       
        <!--Profile 1 sections-->
        <section id="Testimonial" class="Profile_1">
            <ul>
                <li>
                    “I’m cured! I couldn’t believe it when I got the results. Now the future looks bright for me and<br>the children.”
                </li>
                <li>
                    “My treatment was quite simple – just one pill each morning while the children had their breakfast.”
                </li>
                <li>
                    “The sooner the treatment was done, the sooner we could get on with our lives – it only took<br>2 months.”
                </li>
            </ul>
        </section>
        
        <section id="Keypoints" class="Profile_1">
            <ul>
                <li>
                    Up to <strong>100% cure</strong> in real-world 
                    HCV GT1 treatment-naïve patients 
                    without cirrhosis treated with 8-week 
                    HARVONI (n=558)<sup>1–4,a,b</sup>
                    <button class="P1_popup_1"></button>
                    <div class="P1_popup_1">
                        <img src="/images/Profile_1_popup_1.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    HARVONI offers a single-tablet 
                    regimen for the majority of HCV GT1 
                    patients.<sup>5,c</sup> <strong>96% treatment adherence</strong> 
                    was observed in real-world patients 
                    treated with 8-week HARVONI<sup>3,d</sup>
                    <button class="P1_popup_2"></button>
                    <div class="P1_popup_2">
                        <img src="/images/Profile_1_popup_2.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    <strong>95–100% completion</strong> rates were 
                    seen in real-world patients treated 
                    with<br>8-week HARVONI<sup>1–4</sup>
                    <button class="P1_popup_3"></button>
                    <div class="P1_popup_3">
                        <img src="/images/Profile_1_popup_3.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
            </ul>
        </section>
       
        <!--Profile 2 sections-->
        <section id="Testimonial" class="Profile_2">
            <ul>
                <li>
                    “There’s a lot of stigma around having HCV, especially being coinfected. But now I’m cured, I don’t have to worry about it.”
                </li>
                <li>
                    “I didn’t even have to change my HIV medication – that was such<br>a relief.”
                </li>
                <li>
                    “My job is important and I can’t afford to take time off. With this treatment, I didn’t have to.”
                </li>
            </ul>
        </section>

        <section id="Keypoints" class="Profile_2">
            <ul>
                <li>
                    Up to <strong>100% cure</strong> in real-world HIV/HCV-coinfected patients treated with HARVONI for 8 weeks<sup>1,a,b</sup>
                    <button class="P2_popup_1"></button>
                    <div class="P2_popup_1">
                        <img src="/images/Profile_2_popup_1.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    HARVONI can be <strong>coadministered with all</strong> classes of HIV<br>antiviral agents<sup>2,c</sup>
                    <button class="P2_popup_2"></button>
                    <div class="P2_popup_2">
                        <img src="/images/Profile_2_popup_2.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    HARVONI is <strong>well-tolerated;</strong> up to 100% of real-world patients completed 8-week therapy<br>with HARVONI<sup>1,3,4,d</sup>
                    <button class="P2_popup_3"></button>
                    <div class="P2_popup_3">
                        <img src="/images/Profile_2_popup_3.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
            </ul>
        </section>
       
        <!--Profile 3 sections-->
        <section id="Testimonial" class="Profile_3">
            <ul>
                <li>
                    “My friend who was treated needed ribavirin because of their genotype. My doctor said it wouldn’t<br>be necessary.”
                </li>
                <li>
                    “Of course I would have taken the treatment for as long as needed, but 2 months instead of 3 made things a lot easier.”
                </li>
                <li>
                    “I recently got my blood pressure under control, and I was a bit worried what it would mean for my treatment, but my doctor told me it shouldn’t be a problem.”
                </li>
                <li>
                    “I also take some pills for an ulcer. My doctor said it was important to make sure I took them at the same time or after my HCV tablet. I didn’t find it difficult!”
                </li>
            </ul>
        </section>

        <section id="Keypoints" class="Profile_3">
            <ul>
                <li>
                    8-week HARVONI achieved high cure rates in real-world patients, <strong>regardless of GT1 subtype</strong><sup>1–4,a,b</sup>
                    <button class="P3_popup_1"></button>
                    <div class="P3_popup_1">
                        <img src="/images/Profile_3_popup_1.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    In clinical practice, 8-week HARVONI was <strong>as effective</strong> as 12-week treatment in eligible patients<sup>1,a</sup>
                    <button class="P3_popup_2"></button>
                    <div class="P3_popup_2">
                        <img src="/images/Profile_3_popup_2.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    Up to 100% cure rates were seen in real-world patients with a range<br>of comorbidities<sup>3</sup>
                    <button class="P3_popup_3"></button>
                    <div class="P3_popup_3">
                        <img src="/images/Profile_3_popup_3.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    Coadministration of HARVONI with acid-reducing agents is not contraindicated.<sup>5</sup> In order to ensure maximum absorption of the active components of HARVONI, it is important to adhere to the recommended dosage timings.<sup>5</sup>
                    <button class="P3_popup_4"></button>
                    <div class="P3_popup_4">
                        <img src="/images/Profile_3_popup_4.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
            </ul>
        </section>
       
        <!--Profile 4 sections-->
        <section id="Testimonial" class="Profile_4">
            <ul>
                <li>
                    “They told me my liver was quite bad, but I got cured anyway.”
                </li>
                <li>
                    “I wouldn’t have done the<br>treatment if I’d needed to stop<br>my methadone.”
                </li>
                <li>
                    “I can forget things, but I took my tablets every day like the doctor told me to.”
                </li>
            </ul>
        </section>

        <section id="Keypoints" class="Profile_4">
            <ul>
                <li>
                    8-week treatment with HARVONI resulted in consistently high cure rates in patients <strong>without cirrhosis, regardless of fibrosis score</strong><sup>1,a,b</sup>
                    <button class="P3_popup_1"></button>
                    <div class="P3_popup_1">
                        <img src="/images/Profile_4_popup_1.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    <strong>No dose adjustment</strong> is required<br>when coadministering HARVONI<br>with narcotics<sup>2,c</sup>
                    <button class="P3_popup_2"></button>
                    <div class="P3_popup_2">
                        <img src="/images/Profile_4_popup_2.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
                <li>
                    <strong>96% treatment adherence</strong> was observed in real-world patients treated with 8-week HARVONI<sup>3,d</sup>
                    <button class="P3_popup_3"></button>
                    <div class="P3_popup_3">
                        <img src="/images/Profile_4_popup_3.jpg">
                        <span class="close_btn"></span>
                    </div>
                </li>
            </ul>
        </section>

        
        <!--Footer used for main footnotes-->
        <footer>
           <!--TODO: format footer here-->
            <div class="refs refScreensaver">
                <ol class="footnote">
                    <li>Cure rates of 95–100% were observed in four real-world studies of treatment-naïve HCV GT1 patients without cirrhosis, treated with 8-week HARVONI.<sup>1–4</sup></li>
                    <li>Patients in real world studies reported comorbidities including depression, arterial hypertension, aortic sclerosis, and anaemia.<sup>3</sup></li>
                    <br>
                </ol>
                
                <ol>
                    <li>Terrault N <i>et al</i>. Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study. Oral 94 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.natap.org/2015/AASLD/AASLD_04.htm. Accessed February 2016.</li>

                    <li>Curry MP <i>et al</i>. Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network. Poster 1046 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://triohealth.com/<br>wp-content/uploads/2015/11/Poster-Study-1-Final.pdf. Accessed February 2016.</li>

                    <li>Buggisch P <i>et al</i>. Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment. Poster 1205 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.ifi-medizin.de/files/ifi_content/pdf/2015_AASLD_PN1205.pdf. Accessed February 2016.</li>

                    <li>Christensen S <i>et al</i>. Sofosbuvir and ledipasvir for 8 weeks in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice – Results from the German hepatitis C Cohort (GECCO). Poster 1081 presented at <br>the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.natap.org/2015/AASLD/AASLD_188.htm. Accessed February 2016</li>
                </ol>
            </div>

            <div class="refs Profile_1">
                <ol class="footnote">
                    <li>Treatment-naïve HCV GT1 patients without cirrhosis may be considered for 8-week treatment with HARVONI.<sup>5</sup></li>
                    <li>EASL defines cure as SVR12.<sup>6</sup></li>
                    <li>HARVONI offers a single-tablet regimen option for the majority of HCV GT1 patients. RBV is recommended for the treatment of patients with decompensated cirrhosis, and those post-liver transplant<sup>5</sup></li>
                    <li>Evidence of non-adherence was assessed upon the discretion of the investigators, and based on patient adherence to schedules and appointments, patient statements and congruence to the prescriptions.<sup>3</sup></li>
                    <br>
                </ol>

                <ol>
                    <li>Terrault N <i>et al</i>. Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study. Oral 94 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.natap.org/2015/AASLD/AASLD_04.htm. Accessed February 2016.</li>
                    
                    <li>Curry MP <i>et al</i>. Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network. Poster 1046 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://triohealth.com/wp-content/uploads/2015/11/Poster-Study-1-Final.pdf. Accessed February 2016.</li>
                    
                    <li>Buggisch P <i>et al</i>. Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment. Poster 1205 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.ifi-medizin.de/files/ifi_content/pdf/2015_AASLD_PN1205.pdf. Accessed February 2016.</li>
                    
                    <li>Christensen S <i>et al</i>. Sofosbuvir and ledipasvir for 8 weeks in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice – Results from the German hepatitis C Cohort (GECCO). Poster 1081 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.natap.org/2015/AASLD/AASLD_188.htm. Accessed February 2016.</li>

                    <li>HARVONI Summary of Product Characteristics, January 2016.</li>

                    <li>European Association for the Study of the Liver (EASL). Recommendations on Treatment of Hepatitis <i>C. J Hepatol</i> 2015;63:199–236.</li>
                </ol>
            </div>

            <div class="refs Profile_2">
                <ol class="footnote">
                    <li>Treatment-naïve HCV GT1 patients without cirrhosis may be considered for 8-week treatment with HARVONI.<sup>2</sup></li>
                    <li>EASL defines cure as SVR12.<sup>5</sup></li>
                    <li>Please refer to HARVONI Summary of Product Characteristics for full details of drug-drug interactions. HARVONI has been shown to increase TDF exposure when used together with an HIV regimen containing TDF and a pharmacokinetic enhancer (ritonavir or cobicistat).<sup>2</sup> The safety of TDF in the setting of HARVONI and a pharmacokinetic enhancer has not been established. Patients receiving HARVONI concomitantly with Stribild<span class="triangle"></span> or with TDF and a boosted HIV PI should be monitored for TDF-associated adverse reactions.<sup>2</sup></li>
                    <li>2% (31/1648) discontinued treatment early. This includes patients treated with 8, 12, 24 and other weeks of HARVONI ± RBV.<sup>1</sup></li>
                    <br>
                </ol>

                <ol>
                    <li>Christensen S <i>et al</i>. Sofosbuvir and ledipasvir for 8 weeks in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice – Results from the German hepatitis C Cohort (GECCO). Poster 1081 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.natap.org/2015/AASLD/AASLD_188.htm. Accessed February 2016.</li>

                    <li>HARVONI Summary of Product Characteristics, January 2016.</li>

                    <li>Curry MP <i>et al</i>. Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network. Poster 1046 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://triohealth.com/wp-content/uploads/2015/11/Poster-Study-1-Final.pdf. Accessed February 2016.</li>

                    <li>Buggisch P <i>et al</i>. Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment. Poster 1205 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.ifi-medizin.de/files/ifi_content/pdf/2015_AASLD_PN1205.pdf. Accessed February 2016.</li>

                    <li>Terrault N <i>et al</i>. Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study. Oral 94 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.natap.org/2015/AASLD/AASLD_04.htm. Accessed February 2016.</li>

                    <li>European Association for the Study of the Liver (EASL). Recommendations on Treatment of Hepatitis <i>C. J Hepatol</i> 2015;63:199–236.</li>
                </ol>
            </div>

            <div class="refs Profile_3">
                <ol class="footnote">
                    <li>Treatment-naïve HCV GT1 patients without cirrhosis may be considered for 8-week treatment with HARVONI.<sup>5</sup></li>
                    <li>EASL defines cure as SVR12.<sup>6</sup></li>
                    <br>
                </ol>

                <ol>
                    <li>Terrault N <i>et al</i>. Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study. Oral 94 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.natap.org/2015/AASLD/AASLD_04.htm. Accessed February 2016.</li>

                    <li>Curry MP <i>et al</i>. Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network. Poster 1046 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://triohealth.com/wp-content/uploads/2015/11/Poster-Study-1-Final.pdf. Accessed February 2016.</li>

                    <li>Buggisch P <i>et al</i>. Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment. Poster 1205 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.ifi-medizin.de/files/ifi_content/pdf/2015_AASLD_PN1205.pdf. Accessed February 2016.</li>

                    <li>Christensen S <i>et al</i>. Sofosbuvir and ledipasvir for 8 weeks in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice – Results from the German hepatitis C Cohort (GECCO). Poster 1081 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.natap.org/2015/AASLD/AASLD_188.htm. Accessed February 2016.</li>

                    <li>HARVONI Summary of Product Characteristics, January 2016.</li>

                    <li>European Association for the Study of the Liver (EASL). Recommendations on Treatment of Hepatitis <i>C. J Hepatol</i> 2015;63:199–236.</li>
                </ol>
            </div>

            <div class="refs Profile_4">
                <ol class="footnote">
                    <li>Treatment-naïve HCV GT1 patients without cirrhosis may be considered for 8-week treatment with HARVONI.<sup>2</sup></li>
                    <li>EASL defines cure as SVR12.<sup>4</sup></li>
                    <li>Please refer to the HARVONI Summary of Product Characteristics for full details of drug-drug interactions.<br>
                    <li>Evidence of non-adherence was assessed upon the discretion of the investigators, and based on patient adherence to schedules and appointments, patient statements and congruence to the prescriptions.<sup>3</sup></li>
                    <br>
                </ol>

                <ol>
                    <li>Curry MP <i>et al</i>. Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network. Poster 1046 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://triohealth.com/wp-content/uploads/2015/11/Poster-Study-1-Final.pdf. Accessed February 2016.</li>

                    <li>HARVONI Summary of Product Characteristics, January 2016.</li>

                    <li>Buggisch P <i>et al</i>. Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment. Poster 1205 presented at the Liver Meeting 2015, San Francisco, CA, USA, 2015. Available from http://www.ifi-medizin.de/files/ifi_content/pdf/2015_AASLD_PN1205.pdf. Accessed February 2016.</li>

                    <li>European Association for the Study of the Liver (EASL). Recommendations on Treatment of Hepatitis <i>C. J Hepatol</i> 2015;63:199–236.</li>
                </ol>
            </div>
        </footer>
        
        
        <div id="BG_source">
            <video autoplay loop>
                <source src="video/Profile_1_BG.mp4" type="video/mp4">
            </video>
        </div>
    </section>

    <div id="IdleModal">
        <p>You have been inactive for a while, close the window to continue or the app will reset in:</p>
        <span class="countdown">20</span>
        <div class="close_btn"></div>
    </div>


</body>

</html>